Tofacitinib
Tofacitinib May Effectively Alleviate Pain in RA, Psoriatic Arthritis, and Ankylosing Spondylitis
June 20, 2018Tofacitinib may provide a fast and prolonged analgesic effect in patients with rheumatoid arthritis or psoriatic arthritis who are unresponsive to csDMARD or to TNFi, as well as in individuals with ankylosing spondylitis.
Tocilizumab Linked to Anemia Marker Improvement in Rheumatoid Arthritis
September 11, 2017Tocilizumab was associated with significant improvements in hemoglobin and hematocrit over 2 years of treatment in patients with rheumatoid arthritis.
Low Disease Activity in Rheumatoid Arthritis After Tofacitinib Discontinuation
June 01, 2017Approximately 1 in 3 patients with RA who discontinued tofacitinib maintained low disease activity after 1 year.
Clinical Pain Advisor Articles
- Supervised Injection Sites: Facts, Information, Pros, and Cons
- Chronic Pain May Be a Contributing Factor to Suicide
- Striking a Balance Between Opioid Surveillance and Patient Privacy
- Demographic Characteristics of Pregnant Women With Opioid Use Disorder
- Effects of Mindfulness Therapy, Pharmacologic Prophylaxis on Catecholamine Levels in Migraine
- Perioperative Pain Management in Patients With Opioid Use Disorder
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Reviewing the Efficacy of Intrathecal Morphine, Ziconotide for Cancer- and Noncancer Chronic Pain
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Factors Associated With Suboptimal Interscalene Brachial Plexus Block for Arthroscopy
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- Scholarship Support Limited for Veterans Enrolling in MD Programs
- Alpha and Beta Band Activity in MS-Related Chronic Pain
- New Opioid-Induced Constipation Management Guidelines Available
